{
    "nctId": "NCT03955939",
    "briefTitle": "A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body",
    "officialTitle": "A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Number of Participants with Dose Reductions",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must have hormone receptor positive and HER2 negative metastatic breast cancer\n* Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor\n* Participant must be able and willing to undergo mandatory tumor biopsy\n* Participant must have normal organ function\n* Participant must be able to swallow capsules\n\nExclusion Criteria:\n\n* Participant must not have had prior chemotherapy for mBC. Chemotherapy in the adjuvant/neoadjuvant setting is permitted\n* Participant must not be currently enrolled in a clinical study\n* Participant must not have another serious medical condition\n* Participant must not have previously received an aurora kinase inhibitor",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}